Production of human lactoferrin in animal milk 1 1 This article is part of a Special Issue entitled Lactoferrin and has undergone the Journal's usual peer review process.

Institute of Gene Biology, Russian Academy of Sciences, 119334, Vavilova str, 34/5, Moscow, Russia.
Biochemistry and Cell Biology (Impact Factor: 2.15). 02/2012; 90(3):513-9. DOI: 10.1139/o11-088
Source: PubMed


Genetic constructs containing the human lactoferrin (hLf) gene were created within a joint program of Russian and Belorussian scientists. Using these constructs, transgenic mice were bred (the maximum hLf concentration in their milk was 160 g/L), and transgenic goats were also generated (up to 10 g/L hLf in their milk). Experimental goatherds that produced hLf in their milk were also bred, and the recombinant hLf was found to be identical to the natural protein in its physical and chemical properties. These properties included electrophoretic mobility, isoelectric point, recognition by polyclonal and monoclonal antibodies, circular dichroic spectra, interaction with natural ligands (DNA, lipopolysaccharides, and heparin), the binding of iron ions, the sequence of the 7 terminal amino acids, and its biological activity. The latter was assessed by the agglutination of Micrococcus luteus protoplasts, bactericidal activity against Escherichia coli and Listeria monocytogenes , and fungicidal activity against Candida albicans . We also demonstrated a significant increase in the activity of antibiotics when used in combination with Lf.

1 Follower
39 Reads
  • Source
    • "Another study investigated the effects of rhLF on anemia and found that rhLF can improve iron status of rats with anemia more than supplementation with ferrous lactate alone (Wang et al. 2012). Lactoferrin is an antimicrobial protein with in vitro bactericidal activity against Escherichia coli and Listeria monocytogenes, and fungicidal activity against Candida albicans, as well as the ability to increase in the activity of antibiotics when used in combination in vitro (Goldman et al. 2012). Using an in vivo model, rhLF beneficially modulated the intestinal flora composition and improved the growth of young pigs (Hu et al. 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Genetic engineering, which was first developed in the 1980s, allows for specific additions to animals' genomes that are not possible through conventional breeding. Using genetic engineering to improve agricultural animals was first suggested when the technology was in the early stages of development by Palmiter et al. (Nature 300:611-615, 1982). One of the first agricultural applications identified was generating transgenic dairy animals that could produce altered or novel proteins in their milk. Human milk contains high levels of antimicrobial proteins that are found in low concentrations in the milk of ruminants, including the antimicrobial proteins lactoferrin and lysozyme. Lactoferrin and lysozyme are both part of the innate immune system and are secreted in tears, mucus, and throughout the gastrointestinal (GI) tract. Due to their antimicrobial properties and abundance in human milk, multiple lines of transgenic dairy animals that produce either human lactoferrin or human lysozyme have been developed. The focus of this review is to catalogue the different lines of genetically engineered dairy animals that produce either recombinant lactoferrin or lysozyme that have been generated over the years as well as compare the wealth of research that has been done on the in vitro and in vivo effects of the milk they produce. While recent advances including the development of CRISPRs and TALENs have removed many of the technical barriers to predictable and efficient genetic engineering in agricultural species, there are still many political and regulatory hurdles before genetic engineering can be used in agriculture. It is important to consider the substantial amount of work that has been done thus far on well established lines of genetically engineered animals evaluating both the animals themselves and the products they yield to identify the most effective path forward for future research and acceptance of this technology.
    Transgenic Research 06/2015; 24(4). DOI:10.1007/s11248-015-9885-5 · 2.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: During the past two decades, there have been numerous attempts at using animals in order to produce recombinant human proteins and monoclonal antibodies. However, it is only recently that the first two therapeutic agents isolated from the milk of transgenic animals, C1 inhibitor (Ruconest) and antithrombin (ATryn), appeared on the market. This inspires hope that a considerable number of new recombinant proteins created using such technology could become available for practical use in the near future. In this review, the methods applied to produce transgenic animals are described and the advantages and drawbacks related to their use for producing recombinant human proteins and monoclonal antibodies are discussed.
    Acta Naturae 04/2013; 5(1):33-46. · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Expression in milk of transgenic farm animals is one of the most effective ways to produce eukaryotic recombinant proteins. In this review, we discuss the problems of the appropriateness of selecting this expression system for the production of proteins and the development characteristics of appropriate production processes.
    Applied Biochemistry and Microbiology 12/2013; 49(9). DOI:10.1134/S0003683813090020 · 0.74 Impact Factor
Show more

Similar Publications